An injectable liposome-anchored teriparatide incorporated gallic acid-grafted gelatin hydrogel for osteoarthritis treatment

Nat Commun. 2023 May 31;14(1):3159. doi: 10.1038/s41467-023-38597-0.

Abstract

Intra-articular injection of therapeutics is an effective strategy for treating osteoarthritis (OA), but it is hindered by rapid drug diffusion, thereby necessitating high-frequency injections. Hence, the development of a biofunctional hydrogel for improved delivery is required. In this study, we introduce a liposome-anchored teriparatide (PTH (1-34)) incorporated into a gallic acid-grafted gelatin injectable hydrogel (GLP hydrogel). We show that the GLP hydrogel can form in situ and without affecting knee motion after intra-articular injection in mice. We demonstrate controlled, sustained release of PTH (1-34) from the GLP hydrogel. We find that the GLP hydrogel promotes ATDC5 cell proliferation and protects the IL-1β-induced ATDC5 cells from further OA progression by regulating the PI3K/AKT signaling pathway. Further, we show that intra-articular injection of hydrogels into an OA-induced mouse model promotes glycosaminoglycans synthesis and protects the cartilage from degradation, supporting the potential of this biomaterial for OA treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Gelatin
  • Hydrogels* / therapeutic use
  • Injections, Intra-Articular
  • Liposomes / therapeutic use
  • Mice
  • Osteoarthritis* / drug therapy
  • Phosphatidylinositol 3-Kinases
  • Teriparatide / therapeutic use

Substances

  • Hydrogels
  • Liposomes
  • Gelatin
  • Teriparatide
  • Phosphatidylinositol 3-Kinases

Associated data

  • figshare/10.6084/m9.figshare.22634641